IDEXX Laboratories, Inc. (FRA:IX1)

Market Cap	43.08B +17.0%
Revenue (ttm)	3.67B +10.4%
Net Income	902.35M +19.3%
EPS	11.14 +22.6%
Shares Out	n/a
PE Ratio	47.75
Forward PE	43.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	7
Open	535.40
Previous Close	536.20
Day's Range	535.40 - 535.40
52-Week Range	325.20 - 665.80
Beta	n/a
RSI	38.89
Earnings Date	Feb 2, 2026

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1983
• Employees: 11,000
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IX1

Financial Performance

In 2025, IDEXX Laboratories's revenue was $4.30 billion, an increase of 10.42% compared to the previous year's $3.90 billion. Earnings were $1.06 billion, an increase of 19.33%.

Financial numbers in USD